6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      High density lipoprotein cholesterol / C reactive protein ratio in heart failure with preserved ejection fraction

      research-article
      1 , 1 , , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 2 , 3 , 2 , 4 , 3 , 5 , 6 , 7 , 7 , 7 , 7 , Osaka CardioVascular Conference (OCVC)‐Heart Failure Investigators
      ESC Heart Failure
      John Wiley and Sons Inc.
      Heart failure with preserved ejection fraction, Inflammation, High density lipoprotein cholesterol/C reactive protein ratio, Left ventricular diastolic function, Right ventricular systolic function

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Aims

          The impacts of high density lipoprotein cholesterol (HDL‐C) as an anti‐inflammatory and C reactive protein (CRP) as inflammatory properties on the pathogenesis of heart failure were reported. At present, the clinical significance of the HDL‐C/CRP ratio in heart failure with preserved ejection fraction (HFpEF) patients remains unknown.

          Methods and results

          We examined the data on 796 consecutive HFpEF (left ventricular ejection fraction ≥50%) patients hospitalized due to acute decompensated heart failure from the PURSUIT‐HFpEF registry, a prospective, multicentre observational study. We calculated the HDL/CRP ratios and evaluated the relationship between the values and clinical outcomes, including degree of cardiac function. The mean follow‐up duration was 420 ± 346 days. All‐cause death occurred in 118 patients, of which 51 were cardiac deaths. HDL/CRP ≤ 4.05 was independently and significantly associated with all‐cause death (odds ratio = 1.84, 95% CI: 1.06–3.20, P = 0.023), and HDL/CRP ≤ 3.14 was associated with cardiac death by multivariate Cox proportional hazard analysis (odds ratio = 2.86, 95% CI: 1.36–6.01, P = 0.003). HDL‐C/CRP ratio significantly correlated with the product of the left atrial volume and left ventricular mass index as well as the tricuspid annular plane systolic excursion by multiple regression analysis (standardized beta‐coefficient = −0.085, P = 0.034 and standardized beta‐coefficient = 0.081, P = 0.044, respectively).

          Conclusions

          HDL‐C/CRP ratio was a useful marker for predicting all‐cause death and cardiac death and correlated with left ventricular diastolic function and right ventricular systolic function in HFpEF patients.

          Related collections

          Most cited references43

          • Record: found
          • Abstract: found
          • Article: not found

          Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

          The rapid technological developments of the past decade and the changes in echocardiographic practice brought about by these developments have resulted in the need for updated recommendations to the previously published guidelines for cardiac chamber quantification, which was the goal of the joint writing group assembled by the American Society of Echocardiography and the European Association of Cardiovascular Imaging. This document provides updated normal values for all four cardiac chambers, including three-dimensional echocardiography and myocardial deformation, when possible, on the basis of considerably larger numbers of normal subjects, compiled from multiple databases. In addition, this document attempts to eliminate several minor discrepancies that existed between previously published guidelines.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.

              Over the past decade, myocardial structure, cardiomyocyte function, and intramyocardial signaling were shown to be specifically altered in heart failure with preserved ejection fraction (HFPEF). A new paradigm for HFPEF development is therefore proposed, which identifies a systemic proinflammatory state induced by comorbidities as the cause of myocardial structural and functional alterations. The new paradigm presumes the following sequence of events in HFPEF: 1) a high prevalence of comorbidities such as overweight/obesity, diabetes mellitus, chronic obstructive pulmonary disease, and salt-sensitive hypertension induce a systemic proinflammatory state; 2) a systemic proinflammatory state causes coronary microvascular endothelial inflammation; 3) coronary microvascular endothelial inflammation reduces nitric oxide bioavailability, cyclic guanosine monophosphate content, and protein kinase G (PKG) activity in adjacent cardiomyocytes; 4) low PKG activity favors hypertrophy development and increases resting tension because of hypophosphorylation of titin; and 5) both stiff cardiomyocytes and interstitial fibrosis contribute to high diastolic left ventricular (LV) stiffness and heart failure development. The new HFPEF paradigm shifts emphasis from LV afterload excess to coronary microvascular inflammation. This shift is supported by a favorable Laplace relationship in concentric LV hypertrophy and by all cardiac chambers showing similar remodeling and dysfunction. Myocardial remodeling in HFPEF differs from heart failure with reduced ejection fraction, in which remodeling is driven by loss of cardiomyocytes. The new HFPEF paradigm proposes comorbidities, plasma markers of inflammation, or vascular hyperemic responses to be included in diagnostic algorithms and aims at restoring myocardial PKG activity. Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                mnishino@osakah.johas.go.jp
                Journal
                ESC Heart Fail
                ESC Heart Fail
                10.1002/(ISSN)2055-5822
                EHF2
                ESC Heart Failure
                John Wiley and Sons Inc. (Hoboken )
                2055-5822
                02 May 2021
                August 2021
                : 8
                : 4 ( doiID: 10.1002/ehf2.v8.4 )
                : 2791-2801
                Affiliations
                [ 1 ] Division of Cardiology Osaka Rosai Hospital 3‐1179 Nagasonecho, Kita‐ku, Sakai Osaka 591‐8025 Japan
                [ 2 ] Division of Cardiology Osaka General Medical Center Osaka Japan
                [ 3 ] Division of Cardiology Amagasaki Chuo Hospital Amagasaki Japan
                [ 4 ] Cardiovascular Division Osaka Police Hospital Osaka Japan
                [ 5 ] Department of Medical Informatics Osaka University Graduate School of Medicine Suita Japan
                [ 6 ] Division of Cardiology Kawanishi City Hospital Kawanishi Japan
                [ 7 ] Department of Cardiovascular Medicine Osaka University Graduate School of Medicine Suita Japan
                Author notes
                [*] [* ]Correspondence to: Masami Nishino, Division of Cardiology, Osaka Rosai Hospital, 3‐1179 Nagasonecho, Kita‐ku, Sakai, Osaka 591‐8025, Japan. Tel: +81‐6‐6879‐3640; Fax: +81‐6‐6879‐3639. Email: mnishino@ 123456osakah.johas.go.jp
                [ † ]

                Please see Appendix  A.

                Author information
                https://orcid.org/0000-0003-0309-7023
                Article
                EHF213350 ESCHF-20-01033
                10.1002/ehf2.13350
                8318396
                33934563
                1b40b271-b218-40b7-a372-e3f29af3eab0
                © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

                History
                : 16 February 2021
                : 02 November 2020
                : 26 March 2021
                Page count
                Figures: 3, Tables: 4, Pages: 11, Words: 4113
                Funding
                Funded by: Fuji Film Toyama Chemical Co. Ltd
                Funded by: Roche Diagnostics K.K.
                Categories
                Original Research Article
                Original Research Articles
                Custom metadata
                2.0
                August 2021
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.0.4 mode:remove_FC converted:28.07.2021

                heart failure with preserved ejection fraction,inflammation,high density lipoprotein cholesterol/c reactive protein ratio,left ventricular diastolic function,right ventricular systolic function

                Comments

                Comment on this article